| Literature DB >> 33424267 |
Safaet Alam1, Nazim Uddin Emon2, Saimon Shahriar3, Fahmida Tasnim Richi3, Mohammad Rashedul Haque1, Mohammad Nazmul Islam2, Shahenur Alam Sakib2, Amlan Ganguly4.
Abstract
Millettia peguensis, popular for its ethnopharmacological uses, was employed to evaluate its different pharmacological properties in this study. The analgesic studies of the plant have been performed by acetic acid-induced writhing and formalin-induced licking tests respectively, whereas the antidiarrheal experiment was done by castor oil-induced diarrheal test. Besides, antioxidant, cytotoxic, antimicrobial, thrombolytic evaluations were performed by DPPH scavenging with phenol content determination, brine shrimp lethality, disc diffusion and clot lysis methods respectively. Moreover, in silico study of the phytoconstituents was carried out by molecular docking and ADME/T analysis. The methanol extract of Millettia peguensis (MEMP) revealed significant biological activity in the analgesic and antidiarrheal test (p < 0.001) compared to the standards. Antioxidant assay displayed promising IC50 values (15.96 μg/mL) with the total phenol content (65.27 ± 1.24 mg GAE/g). In the cytotoxicity study, the LC50 value was found to be 1.094 μg/mL. Besides, MEMP was highly sensitive to the bacteria but less liable to clot lysis. Furthermore, phytoconstituents exposed potential binding affinity towards the selected receptors, whereas the ADME/T properties indicated the drug likeliness of the plant. The outcomes of these findings suggest the therapeutic potential of this plant against pain, diarrhea, inflammation, and tissue toxicity.Entities:
Keywords: 5-HT3, 5-hydroxytryptamine 3; ASA, acetyl salicylic acid; Analgesic; Antidiarrheal; Antioxidant; Antitumor; BHT, butylated hydroxytoluene; CADD, computer-aided drug discovery; COX 1, cyclooxygenase-1; COX 2, cyclooxygenase-2; DPPH, 2,2-diphenyl-1-picryl-hydrazyl-hydrate; GABA, gamma-Aminobutyric acid; IC50, half maximal inhibitory concentration; IL-1, interleukin-1; LC50, Lethal Concentration 50; MEMP, methanol extract of Millettia peguensis; MMP 9, matrix metalloproteinase 9; Millettia peguensis; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; RONS, reactive oxygen and nitrogen species; ROS, reactive oxygen species; TNF-alpha, tumour necrosis factor alpha
Year: 2020 PMID: 33424267 PMCID: PMC7783235 DOI: 10.1016/j.jsps.2020.11.004
Source DB: PubMed Journal: Saudi Pharm J ISSN: 1319-0164 Impact factor: 4.330
Fig. 1Structure of selected phytoconstituents.
Analgesic effect of methanol extract of M. peguensis leaves (MEMP) in acetic acid induced writhing test in mice.
| Treatments | Number of abdominal writhings | Inhibition (%) |
|---|---|---|
| TWN – 80 (10 mL/kg) | 17.20 ± 1.30 | – |
| ASA (10 mg/kg) | 3.40 ± 0.24*** | 80.23 |
| MEMP (200 mg/kg) | 8.20 ± 0.37*** | 52.33 |
| MEMP (400 mg/kg) | 5.60 ± 0.24*** | 67.44 |
Values were presented as Mean ± SEM (n = 6); one-way analysis of variance (ANOVA) was followed by Dunnett’s test. *p < 0.05, **p < 0.01 and ***p < 0.001 was considered as significant, compared with standard. TWN = 1% Tween 80, and ASA = Acetylsalicylic acid, SEM = Standard error mean.
Analgesic effect of methanol extract of M. peguensis leaves (MEMP) formalin-induced paw licking test in mice.
| Treatment | Early phase (0–5 min) | Inhibition (%) | Late phase (15–30 min) | Inhibition (%) |
|---|---|---|---|---|
| TWN-80 (10 mL/kg) | 61.23 ± 1.34 | – | 47.11 ± 3.13 | – |
| ASA (10 mg/kg) | 17.55 ± 2.23*** | 71.33 | 13.70 ± 2.45*** | 70.91 |
| MEMP (200 mg/kg) | 38.33 ± 1.37*** | 37.39 | 30.47 ± 2.67** | 35.32 |
| MEMP (400 mg/kg) | 22.57 ± 3.21*** | 63.13 | 20.36 ± 1.97*** | 56.78 |
Values were presented as Mean ± SEM (n = 6); one-way analysis of variance (ANOVA) was followed by Dunnett’s test. *p < 0.05, **p < 0.01 and ***p < 0.001 was considered as significant, compared with standard. TWN = 1% Tween 80, and ASA = Acetylsalicylic acid, SEM = Standard error mean.
Antidiarrheal effect of methanol extract of M. peguensis leaves on castor oil induced test in mice.
| Treatment | Dose, route (p.o) | Onset of diarrhea (min) | Average number of wet feces | Total number of feces | Average weight of wet feces (g) | Average weight of total feces (g) |
|---|---|---|---|---|---|---|
| Group-Ⅰ | 1% tween 80–10 mL/kg | 77.16 ± 1.83 | 8.67 ± 2.19 | 11.17 ± 3.79 | 0.47 ± 0.09 | 0.57 ± 0.03 |
| Group-Ⅱ | Loperamide-3 mg/kg | 189.16 ± 3.91*** | 2.33 ± 2.16*** | 4.16 ± 2.30*** | 0.09 ± 0.01*** | 0.13 ± 0.12*** |
| Group-III | MEMP-200 mg/kg | 139.33 ± 2.93*** | 4.67 ± 3.30** | 6.67 ± 2.13*** | 0.24 ± 0.03*** | 0.32 ± 0.05*** |
| Group-Ⅳ | MEMP-400 mg/kg | 175.67 ± 2.46*** | 3.67 ± 1.21*** | 5.53 ± 3.15*** | 0.16 ± 0.07*** | 0.23 ± 0.07*** |
Values were presented as Mean ± SEM (n = 6); one-way analysis of variance (ANOVA) was followed by Dunnett’s test. *p < 0.05, **p < 0.01 and ***p < 0.001 was considered as significant, compared with control. TWN = 1% Tween 80, and ASA = Acetylsalicylic acid, SEM = Standard error mean.
Quantitative analysis of total phenol content of methanol extract of M. peguensis leaves.
| Plant extract | Total phenol content (mg GAE/g) | Regression Line |
|---|---|---|
| MEMP | 65.27 ± 1.24 | y = 0.0383x + 0.0892, R2 = 0.9446 |
Fig. 2Percentage of radical scavenging activities of methanol extract of M. peguensis leaves and standard drug.
Fig. 3IC50 value of butylated hydroxytoluene (BHT) and methanol extract of M. peguensis leaves.
Fig. 4% Mortality and predicted regression line of vincristine sulphate and methanol extract of M. peguensis leaves.
Fig. 5Clot lysis effects of methanol extract of M. peguensis leaves. Clot lysis values are presented as mean ± SEM (n = 5); One-way analysis of variance (ANOVA) was followed by Dunnett’s test. *p < 0.05, ** p < 0.01, ***p < 0.001 were considered as significant compared with the control, where # is designated as control. SW = Saline water, SK = streptokinase and MEMP = methanol extract of M. peguensis leaves.
Antimicrobial activity of M. peguensis leaves and standard against gram-positive and gram-negative bacterial strains.
| Diameter of Zone of Inhibition (mm) | |||||
|---|---|---|---|---|---|
| Test Microorganisms | MEMP (100 µg/disc) | Amoxicillin (30 µg/disc) | Test Microorganisms | MEMP (100 µg/disc) | Streptomycin (30 µg/disc) |
| Gram positive bacteria | Gram negative bacteria | ||||
| 23 | 38 | 30 | 37 | ||
| 28 | 34 | 32 | 39 | ||
| 32 | 40 | 29 | 38 | ||
| 29 | 39 | 31 | 40 | ||
| 28 | 41 | 25 | 41 | ||
| 27 | 36 | 26 | 35 | ||
| 30 | 37 | 29 | 37 | ||
| 28 | 36 | ||||
| 27 | 36 | ||||
Docking score and glide energy of kanjone, lanceolatin – B, milletenone, ovalitenone, pongamol with prostaglandin – 1 (PDB ID: 2OYE), prostaglandin – 2 (PDB ID: 6COX), 5-HT3 receptor (PDB ID: 5AIN), urate oxidase (PDB ID: 1R4U), protein tyrosine kinase (PDB: 1XKK), E.coli exonuclease I (PDB ID: 1FXX) and human tissue-type plasminogen activator (PDB ID: 1A5H) in kcal/mol.
| Compounds | Analgesic and Anti-inflammatory | Antidiarrheal | Antioxidant | Cytotoxic | Antibacterial | Thrombolytic | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2OYE | 6COX | 5AIN | 1R4U | 1XKK | 1FXX | 1A5H | ||||||||
| Docking score | Glide energy | Docking score | Glide energy | Docking score | Glide energy | Docking score | Glide energy | Docking score | Glide energy | Docking score | Glide energy | Docking score | Glide energy | |
| Aspirin | −6.69 | −27.55 | −5.91 | −27.00 | – | – | – | – | – | – | – | – | – | – |
| Loperamide | – | – | – | – | −6.15 | −45.41 | – | – | – | – | – | – | – | – |
| Ascorbic acid | – | – | – | – | – | – | −4.32 | −27.36 | – | – | – | – | – | – |
| Doxorubicin | – | – | – | – | – | – | – | – | −7.47 | −63.00 | ||||
| Doxycycline | – | – | – | – | – | – | – | – | – | – | −6.35 | −41.23 | – | – |
| Streptokinase | – | – | – | – | – | – | – | – | – | – | – | – | −6.00 | −26.24 |
| Kanjone | −9.38 | −37.96 | −7.70 | −32.28 | −6.01 | −36.57 | – | – | −5.28 | −38.33 | −5.80 | −28.41 | −6.62 | −37.29 |
| Lanceolatin - B | −8.83 | −35.71 | −8.33 | −33.24 | −6.26 | −38.24 | −4.03 | −22.80 | −6.32 | −35.33 | −4.66 | −28.60 | −6.85 | −38.38 |
| Milletenone | −7.43 | −45.15 | −6.41 | −36.58 | −6.94 | −52.45 | −3.92 | −29.64 | −5.34 | −43.25 | −4.11 | −31.33 | −5.81 | −46.49 |
| Ovalitenone | −8.76 | −50.15 | −6.96 | −39.84 | −6.10 | −50.86 | −3.77 | −28.21 | −5.24 | −43.08 | −6.54 | −46.13 | −6.41 | −49.04 |
| Pongamol | −10.42 | −54.91 | −6.27 | −9.64 | −4.68 | −38.49 | −2.96 | −29.87 | −4.83 | −43.73 | −3.31 | −31.08 | −6.07 | −44.02 |
Fig. 63D and 2D representation of docking interaction with standard drugs.A. Aspirin interaction with 2OYE; B. Aspirin interaction with 6COX; C. Loperamide interaction with 5AIN; D. Doxorubicin interaction with 1XKK; E. Streptokinase interaction with 1A5H.
Fig. 73D and 2D representation of the best key interactions in the binding pocket for selected ligands and receptors whether, (A and B) represents prostaglandin – 1 (PDB ID: 2OYE), pongamol; (C and D) represents prostaglandin – 2 (PDB ID: 6COX), lanceolatin – B; (E and F) represents 5-HT3 receptor (PDB ID: 5AIN) and milletenone; respectively.
Fig. 83D and 2D representation of the best key interactions in the binding pocket for selected ligands and receptors whether, (G and H) represents urate oxidase (PDB ID: 1R4U), lanceolatin – B; (I and J) represents protein tyrosine kinase (PDB: 1XKK), lanceolatin – B; (K and L) represents E. coli exonuclease I (PDB ID: 1FXX), ovalitenone; (M and N) represents human tissue-type plasminogen activator (PDB ID: 1A5H) and lanceolatin –B, respectively.
Absorption, distribution, metabolism, excretion, and toxicological (ADME/T) properties of the compounds for good oral bioavailability.
| Molecules | PID | MW (g/mol) | HBD | HBA | LogP (o/w) | HIA | AM | CAR (binary) | PPB (100%) | AOT (kg/moL) |
|---|---|---|---|---|---|---|---|---|---|---|
| Kanjone | 12,305,449 | 292.30 | 0 | 4 | 4.21 | 0.9928 | 0.6700 | 0.5400 | 0.893 | 2.129 |
| Lanceolatin - B | 10,978,265 | 262.26 | 0 | 3 | 4.21 | 0.9906 | 0.6100 | 0.8888 | 1.021 | 2.313 |
| Milletenone | 42,607,652 | 328.32 | 1 | 6 | 3.21 | 0.9881 | 0.6500 | 0.8672 | 1.028 | 2.007 |
| Ovalitenone | 627,910 | 338.32 | 0 | 6 | 3.63 | 0.9765 | 0.6500 | 0.9745 | 0.847 | 1.703 |
| Pongamol | 101,936,575 | 362.43 | 0 | 4 | 5.34 | 0.9904 | 0.6300 | 0.9143 | 0.927 | 3.148 |
PID = PubChem ID, MW = Molecular Weight (acceptance range: <500), HBD = Hydrogen Bond Donor (acceptance range: ≤ 5), HBA = Hydrogen Bond Acceptor: (acceptance range: ≤ 10), LogP = High Lipophilicity (acceptance range: < 5), HIA = Human Intestinal Absorption, AM = AMES Mutagenesis, CAR = Carcinogens, PPB = Plasma Protein Binding, AOT = Acute Oral Toxicity.